Enoblituzumab, a type of ADCC successfully tested in prostate cancer, can block B7-H3 mediated immune suppression and eliminate cancer cells by triggering antibody-dependent cellular cytotoxicity via NK cells [97]. This evidence concerns the gene CD276 and cancer.